Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Web Exclusives
FDA Approvals
Retevmo Receives New FDA Indication for Advanced Solid Tumors with RET Fusion
Read More
FDA Approvals
Pemazyre Receives New Indication for FGFR1-Positive Myeloid/Lymphoid Neoplasms
Read More
FDA Approvals
Imbruvica Now Also Indicated for Children with Chronic Graft-versus-Host Disease
Read More
FDA Approvals
Lytgobi FDA Approved for Intrahepatic Cholangiocarcinoma with FGFR2 Fusion
Read More
FDA Approvals
Enhertu First FDA-Approved Treatment for HER2-Low Breast Cancer
Read More
FDA Approvals
Enhertu First FDA-Approved Drug for HER2-Positive Non–Small-Cell Lung Cancer
Read More
FDA Approvals
Vegzelma a New Biosimilar FDA Approved for the Treatment of 6 Types of Cancer
Read More
Conference Highlights ASCO
Trastuzumab Deruxtecan a New Standard for Patients with HER2-Low Metastatic Breast Cancer
Read More
FDA Approvals
Breyanzi Now FDA Approved for Second-Line Treatment of Large B-Cell Lymphoma
Read More
Conference Highlights ASCO
Black Patients with Cancer and COVID-19 More Likely Than White Patients to Have Therapy Disruptions
Read More
3
4
5
6
7
8
9
Page 6 of 37
Results 51 - 60 of 368